We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Medicare has undergone several major changes since it launched in 1965. And now, with the passage of the Inflation Reduction Act of 2022, it's poised to change again, with several key ...

See the 10 stocks » However, the Centers for Medicare and Medicaid Services (CMS) could soon throw a monkey wrench into Novo Nordisk's momentum. The agency announced last week that Ozempic and ...

Medicare added Novo Nordisk's Ozempic, Wegovy, and Rybelsus to its 2027 drug price negotiations list. This move could force Novo Nordisk to slash the costs of its top drugs. The company should ...

However, the Centers for Medicare and Medicaid Services (CMS) could soon throw a monkey wrench into Novo Nordisk's momentum. The agency announced last week that Ozempic and Wegovy, along with Novo ...

Dec. 14, 2023. (AP Photo/Andrew Harnik, File) WASHINGTON (AP) — Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated ...

The Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare's list of medications that will be negotiated between the government and manufacturers.

In one of its last actions, the Biden administration released the next 15 drugs selected for Medicare negotiation and the blockbuster diabetes drug Ozempic will be among those bargained for this year.

Ozempic and Wegovy are among the 15 additional drugs selected for a list that will be negotiated for lower Medicare prices. Ten other drugs have already been selected for the Medicare list in an ...

The Centers for Medicare & Medicaid Services (CMS) said Friday that it had selected another 15 drugs for its second round of price negotiations, including the popular weight loss drugs Ozempic and ...